(UroToday.com) The diagnostic process may be extensive in patients with non-muscle invasive bladder cancer (NMIBC) who have positive or suspicious urinary cytology when white-light flexible cystoscopy is negative. The next step in management is typically to proceed with resection biopsies and exclusion of upper urinary tract tumors, procedures that are performed in the operating room, which is demanding on both the patient and the healthcare system. Blue light with rigid cystoscopy at the time of transurethral resection of bladder tumors is routinely used as an adjunct to white light rigid cystoscopy, allowing improved detection of malignancy and is recommended by the AUA guidelines.1 At the American Urological Association (AUA) 2020 Virtual Meeting, Marie Andersson, MD, presented results of their study assessing if blue light flexible cystoscopy can detect more bladder tumors at the outpatient clinic and how blue light flexible cystoscopy can improve the diagnostic process in patients with normal white light flexible cystoscopy and positive or suspicious cytology.